The American College of Cardiology (ACC) meeting is in full swing this week in Chicago and much of the early buzz being generated is around a new class of LDL cholesterol-lowering drugs known as proprotein converase subtilisin/kexin type 9 (PCSK-9) antibodies.?? Inhibitors of PCSK-9 have been pursued for almost a decade.?? However, clinical data are ...
FEEDS
